TY -的T1 - CSF胶质标记与生存在肌萎缩性脊髓侧索硬化症JF -神经学乔-神经病学SP - 982 LP - 987 - 10.1212 / WNL。首页0 b013e3181d5dc3b六世非盟- 74 - 12 - s d Sussmuth AU -公元Sperfeld AU - a·海因茨盟- j . Brettschneider AU - s Endruhn AU - a·c·Ludolph盟- h . Tumani Y1 - 2010/03/23 UR - //www.ez-admanager.com/content首页/74/12/982.abstract N2 -背景:在神经退行性疾病如肌萎缩性脊髓侧索硬化症(ALS),脑脊液生物标志物越来越为鉴别诊断评估他们的相关性,研究疾病进展,对病理生理的过程的理解。目的:确定一个生物标记的神经元和神经胶质脑脊液蛋白歧视ALS与其他运动神经元病(MND),并评估基线水平的ALS CSF措施是否与课程相关的疾病。方法:连续共有122名受试者MND是包含在这个横断面研究(肌萎缩性侧索硬化症,n = 75;下运动神经元综合症,n = 39;上运动神经元疾病,n = 8)。临床随访包括76例。我们确定基线水平的蛋白质τ和astroglial S100beta CSF和小胶质sCD14脑脊液和血清与诊断、疾病、持续时间和生存。结果:脑脊液τ显著升高在ALS和上运动神经元疾病相比下运动神经元疾病和控制。CSF S100beta水平显著低于低比其他MND运动神经元疾病。脑脊液浓度S100beta和sCD14与ALS患者的生存时间。 Conclusions: In motor neuron diseases, CSF tau elevation indicates the degeneration of upper motor neurons, while S100 beta and sCD14 may indicate the activation of CNS glial cells. Because S100beta and sCD14 concentrations correlate with survival in amyotrophic lateral sclerosis (ALS), we suppose that the combination of both markers may be useful to obtain prognostic information in patients with ALS. ALS=amyotrophic lateral sclerosis; ALSFRS=Amyotrophic Lateral Sclerosis Functional Rating Scale; HSP=hereditary spastic paraplegia; LMN=lower motor neuron; LMND=lower motor neuron disease; MND=motor neuron disease; MRCS=Medical Research Council Sumscore; PLS=primary lateral sclerosis; ROC=receiver operating characteristic; UMN=upper motor neuron. ER -